Targeting Protein Kinase CK2: Evaluating CX-4945 Potential for GL261 Glioblastoma Therapy in Immunocompetent Mice

Glioblastoma (GBM) causes poor survival in patients even with aggressive treatment. Temozolomide (TMZ) is the standard chemotherapeutic choice for GBM treatment but resistance always ensues. Protein kinase CK2 (CK2) contributes to tumour development and proliferation in cancer, and it is overexpress...

Descripción completa

Detalles Bibliográficos
Autores principales: Ferrer-Font, Laura, Villamañan, Lucia, Arias-Ramos, Nuria, Vilardell, Jordi, Plana, Maria, Ruzzene, Maria, Pinna, Lorenzo A., Itarte, Emilio, Arús, Carles, Candiota, Ana Paula
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5374428/
https://www.ncbi.nlm.nih.gov/pubmed/28208677
http://dx.doi.org/10.3390/ph10010024

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5374428/
https://www.ncbi.nlm.nih.gov/pubmed/28208677
http://dx.doi.org/10.3390/ph10010024

Ejemplares similares